Co-Administration of LDX (SPD489) and Venlafaxine XR (EFFEXOR XR) in Healthy Volunteers

This study has been completed.
Sponsor:
Information provided by (Responsible Party):
Shire
ClinicalTrials.gov Identifier:
NCT01235338
First received: November 2, 2010
Last updated: March 27, 2013
Last verified: March 2013
  Purpose

This study will examine the effects of co-administration of SPD489 and the antidepressant EFFEXOR XR on the pharmacokinetics of lisdexamfetamine, d-amphetamine, and EFFEXOR XR. In addition, serial blood pressure and pulse measures will be obtained and examined to ensure that there are no unexpected changes in vital signs following co administration of SPD489 and EFFEXOR XR that would impact the further study of this drug combination. The hypothesis is that a drug drug interaction could possibly exist.


Condition Intervention Phase
Healthy
Drug: LDX + Venlafaxine XR
Drug: Venlafaxine XR + LDX
Phase 1

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase 1, Open-label, Drug Interaction Study Evaluating the Pharmacokinetic Profiles of SPD489 and EFFEXOR XR, Administered Alone and in Combination in Healthy Adult Subjects

Resource links provided by NLM:


Further study details as provided by Shire:

Primary Outcome Measures:
  • Maximum Plasma Concentration (Cmax) of Lisdexamfetamine Dimesylate [ Time Frame: Day 15 and Day 30 (24 hour sampling) ] [ Designated as safety issue: No ]
    Lisdexamfetamine dimesylate (SPD489) itself is inactive, but following oral administration is converted to the active isomer, d-amphetamine, that is responsible for the drug's therapeutic activity.

  • Cmax of d-Amphetamine [ Time Frame: Day 15 and Day 30 (24 hour sampling) ] [ Designated as safety issue: No ]
    d-Amphetamine is the active isomer of Lisdexamfetamine dimesylate (SPD489) and is responsible for the drug's therapeutic activity.

  • Cmax of Venlafaxine Hydrochloride [ Time Frame: Day 15 and Day 30 (24 hour sampling) ] [ Designated as safety issue: No ]
    Venlafaxine Hydrochloride is the active ingredient of Effexor XR

  • Cmax of o-Desmethylvenlafaxine [ Time Frame: Day 15 and Day 30 (24 hour sampling) ] [ Designated as safety issue: No ]
    Venlafaxine, after oral administration, is metabolized in the liver to an active metabolite, o-Desmethylvenlafaxine.

  • Cmax of Composite (Venlafaxine + o-Desmethylvenlafaxine) [ Time Frame: Day 15 and Day 30 (24 hour sampling) ] [ Designated as safety issue: No ]
  • Area Under the Steady-state Plasma Concentration-time Curve (AUC) of Lisdexamfetamine Dimesylate [ Time Frame: Day 15 and Day 30 (24 hour sampling) ] [ Designated as safety issue: No ]
  • AUC of d-Amphetamine [ Time Frame: Day 15 and Day 30 (24 hour sampling) ] [ Designated as safety issue: No ]
  • AUC of Venlafaxine Hydrochloride [ Time Frame: Day 15 and Day 30 (24 hour sampling) ] [ Designated as safety issue: No ]
  • AUC of o-Desmethylvenlafaxine [ Time Frame: Day 15 and Day 30 (24 hour sampling) ] [ Designated as safety issue: No ]
  • AUC of Composite (Venlafaxine + o-Desmethylvenlafaxine) [ Time Frame: Day 15 and Day 30 (24 hour sampling) ] [ Designated as safety issue: No ]
  • Time of Maximum Plasma Concentration (Tmax) of Lisdexamfetamine Dimesylate [ Time Frame: Day 15 and Day 30 (24 hour sampling) ] [ Designated as safety issue: No ]
  • Tmax of d-Amphetamine [ Time Frame: Day 15 and Day 30 (24 hour sampling) ] [ Designated as safety issue: No ]
  • Tmax of Venlafaxine Hydrochloride [ Time Frame: Day 15 and Day 30 (24 hour sampling) ] [ Designated as safety issue: No ]
  • Tmax of o-Desmethylvenlafaxine [ Time Frame: Day 15 and Day 30 (24 hour sampling) ] [ Designated as safety issue: No ]
  • Tmax of Composite (Venlafaxine + o-Desmethylvenlafaxine) [ Time Frame: Day 15 and Day 30 (24 hour sampling) ] [ Designated as safety issue: No ]

Secondary Outcome Measures:
  • Systolic Blood Pressure [ Time Frame: Baseline and up to 39 days ] [ Designated as safety issue: Yes ]
  • Diastolic Blood Pressure [ Time Frame: Baseline and up to 39 days ] [ Designated as safety issue: Yes ]
  • Pulse Rate [ Time Frame: Baseline and up to 39 days ] [ Designated as safety issue: Yes ]

Enrollment: 80
Study Start Date: November 2010
Study Completion Date: January 2011
Primary Completion Date: December 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: LDX (SPD489) + Venlafaxine XR (Effexor XR) Drug: LDX + Venlafaxine XR
  • Day 1-5 LDX 30mg
  • Day 6-10 LDX 50mg
  • Day 11-15 LDX 70mg
  • Day 16-20 LDX 70mg and Venlafaxine XR 75mg daily
  • Day 21-25 LDX 70mg and Venlafaxine XR 150mg daily
  • Day 26-30 LDX 70mg and Venlafaxine XR 225mg daily
  • Day 31-34 Venlafaxine XR 150mg daily
  • Day 35-38 Venlafaxine XR 75mg daily.
Other Name: Lisdexamfetamine dimesylate, LDX, Vyvanse, SPD489; Venlafaxine hydrochloride extended-release, Effexor XR,
Experimental: Venlafaxine XR + LDX Drug: Venlafaxine XR + LDX
  • Day 1-5 Venlafaxine XR 75mg
  • Day 6-10 Venlafaxine XR 150mg
  • Day 11-15 Venlafaxine XR 225mg
  • Day 16-20 Venlafaxine XR 225mg and LDX 30mg daily
  • Day 21-25 Venlafaxine XR and LDX 50mg daily
  • Day 26-30 Venlafaxine XR 225mg and LDX 70mg daily
  • Day 31-34 Venlafaxine XR 150mg
  • Day 35-38 Venlafaxine XR 75mg.
Other Name: Venlafaxine hydrochloride extended-release, Effexor XR; Lisdexamfetamine dimesylate, LDX, Vyvanse, SPD489

  Eligibility

Ages Eligible for Study:   18 Years to 45 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  1. Age 18-45 years
  2. Subject is willing to comply with any applicable contraceptive requirements of the protocol and is:

    • Male, or
    • Non-pregnant, non-lactating female
    • Females must be at least 90 days post partum or nulliparous.
  3. Female subjects must have a negative serum beta Human Chorionic Gonadotropin (HCG) pregnancy test
  4. Satisfactory medical assessment
  5. Ability to provide information on family history of hypertension.
  6. Body Mass Index (BMI) between 18.5 and 30.0kg/m² inclusive.
  7. Ability to swallow all investigational products.

Exclusion Criteria:

  1. Current or recurrent disease (e.g., cardiovascular, renal, liver, gastrointestinal, malignancy or other conditions)
  2. Current or relevant previous history of physical or psychiatric illness.
  3. Significant illness.
  4. History of significant anxiety, tension, or agitation as assessed by the Investigator.
  5. History of or current diagnosis of glaucoma.
  6. History of a seizure disorder (other than infantile febrile seizures), any tic disorder or a current diagnosis and/or known family history of Tourette's Disorder.
  7. History of symptomatic cardiovascular disease, advanced arteriosclerosis, structural cardiac abnormality, cardiomyopathy, serious heart rhythm abnormalities, coronary artery disease, transient ischemic attack or stroke, or other serious cardiac problems.
  8. History of controlled or uncontrolled hypertension or a resting sitting systolic BP >139mmHg or diastolic BP >89mmHg.
  9. Known family history of sudden cardiac death or ventricular arrhythmia.
  10. Suicidal ideation or any lifetime history of suicidal behavior.
  11. Consumption of alcohol, Seville oranges, grapefruit, or any grapefruit containing products within 7 days of first dose of investigational product.
  12. Current use of any medication (including prescription, over the counter [OTC], herbal or homeopathic preparations or supplements) with the exception of the occasional dose of acetaminophen, or hormonal contraceptives.
  13. History of alcohol or other substance abuse within the last year.
  14. A positive screen for alcohol or drugs of abuse.
  15. Male subjects who consume more than 21 units of alcohol per week or 3 units per day. Female subjects who consume more than 14 units of alcohol per week or 2 units per day. [1 alcohol unit =1 beer = 1 wine (5oz) = 1 liquor (1.5oz) = 0.75oz alcohol]
  16. A positive human immunodeficiency virus (HIV) antibody screen, Hepatitis B surface antigen (HBsAg), or Hepatitis C virus (HCV) antibody screen.
  17. Use of tobacco in any form (e.g., smoking or chewing) or other nicotine-containing products in any form (e.g. gum, patch). Ex-users must report that they have stopped using tobacco for at least 30 days prior to receiving the first dose of investigational product.
  18. Routine consumption of more than 2 units of caffeine per day or subjects who experience caffeine withdrawal headaches. (One caffeine unit is contained in the following items: one 6oz. cup of coffee, two 12oz. cans of cola, one 12oz. cup of tea, three 1oz. chocolate bars, or one 8oz. serving of an energy drink. Decaffeinated coffee, tea, or cola are not considered to contain caffeine).
  19. Donation of blood or blood products (e.g., plasma or platelets) within 60 days prior to receiving the first dose of investigational product.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01235338

Locations
United States, Florida
Clinical Pharmacology of Miami
Miami, Florida, United States, 33014
Sponsors and Collaborators
Shire
  More Information

Additional Information:
No publications provided

Responsible Party: Shire
ClinicalTrials.gov Identifier: NCT01235338     History of Changes
Other Study ID Numbers: SPD489-117
Study First Received: November 2, 2010
Results First Received: November 4, 2011
Last Updated: March 27, 2013
Health Authority: United States: Food and Drug Administration

Additional relevant MeSH terms:
Venlafaxine
Dextroamphetamine
Serotonin Uptake Inhibitors
Neurotransmitter Uptake Inhibitors
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Serotonin Agents
Physiological Effects of Drugs
Antidepressive Agents, Second-Generation
Antidepressive Agents
Psychotropic Drugs
Central Nervous System Agents
Therapeutic Uses
Dopamine Uptake Inhibitors
Dopamine Agents
Central Nervous System Stimulants

ClinicalTrials.gov processed this record on July 22, 2014